News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

PDF 12.4 KB


Berlin, Germany – Epigenomics AG (ISIN: DE000A0BVT96) today signed an option agreement in colorectal cancer blood testing with QIAGEN N.V. (ISIN: NL0000240000).

Under the terms of the agreement, QIAGEN receives an option to a worldwide non-exclusive commercial license to Epigenomics’ proprietary mSEPT9 biomarker and DNA methylation technologies for the detection of colorectal cancer in blood. The option can be exercised by QIAGEN within the next two years. Furthermore, Epigenomics has granted QIAGEN a research license to the mSEPT9 biomarker and the technologies. Under this license, QIAGEN is currently developing a novel sample preparation technology that meets the requirements for the future broad implementation of methylation-based molecular diagnostics, such as Septin9-targeted blood testing for the detection of colorectal cancer, on QIAGEN’s modular molecular testing platform QIAsymphony. Epigenomics will support QIAGEN in the R&D phase through know-how transfer and the collection of clinical specimens as required.

Under the terms of the option agreement, Epigenomics will receive an upfront payment from QIAGEN and will be reimbursed for any R&D support and clinical specimens provided during the R&D phase. Upon QIAGEN exercising the option Epigenomics would receive a further license payment. Once QIAGEN commercializes a colorectal cancer blood test based on Epigenomics’ biomarkers and technology, Epigenomics would be entitled to royalties on QIAGEN’s net sales as well as certain commercial milestones upon reaching specific revenue targets.

-End of Ad hoc-

Further Information

For further information please see the press release issued today by Epigenomics AG at

Contact Epigenomics AG
Dr. Achim Plum
Sen. VP Corporate Development
Epigenomics AG
Tel +49 (0) 30 24345 0

Epigenomics’ legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.